SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Kirk's Market Thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Kirk © who wrote (12053)10/2/2021 1:43:04 PM
From: robert b furman  Respond to of 26763
 
Thank you for your kind words Kirk,

Have a great dim sum meal and a good game!

Bob



To: Kirk © who wrote (12053)10/2/2021 2:32:47 PM
From: w0z1 Recommendation

Recommended By
Winfastorlose

  Respond to of 26763
 
FYI Fluvoxamine is a second line agent for FLCCC's EARLY TREATMENT PROTOCOL3 (for Delta variant), so some open minded organizations are aware of it.



However, they rank it below their first line agents below:




To: Kirk © who wrote (12053)10/3/2021 5:19:32 PM
From: Sun Tzu  Respond to of 26763
 
Why don't you ask Abbot? Tell them that you are an investor and a newsletter writer and you want to know.
You could also ask the primary researchers in WSU.
>> I looked it up on the clinical trials site and my reading of the results is the one study had fantastic results... so why no follow-up?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News